FDA Lifts Clinical Hold On Viking Therapeutics’ Rare Metabolic Disorder Study
The FDA has lifted the clinical hold placed on Viking Therapeutics Inc’s (NASDAQ:VKTX) trial of VK0214 in patients with X-linked adrenoleukodystrophy (X-ALD). …
The Daily Biotech Pulse: FDA Tentatively Approves Avadel’s Narcolepsy Drug, European Approval Broadens AstraZeneca’s Enhertu in Breast Cancer, Pharma Giants’ Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours:
Tesla In Yet Another Legal Soup After German Suit Over Carbon Emission, Data Privacy
Tesla Inc (NASDAQ:TSLA) has landed in another legal soup as Germany’s largest consumer protection group, the Federation of German…
Johnson & Johnson Cuts Annual Profit Outlook, Pharma Unit Cushions Fall In Medical Devices
Johnson & Johnson (NYSE:JNJ) has reported Q2 FY22 adjusted earnings of $2.59 per share, up 4.4% Y/Y and slightly ahead…
Novartis Posts Mixed Q2 Earnings, Expects Improved Earnings At Sandoz
Novartis AG (NYSE:NVS) has reported a core EPS of $1.56 in Q2 FY22 compared to $1.66 a year ago, beating the…
HC Wainwright Is Bullish On DICE Therapeutics – Read Why
H.C. Wainwright analyst Emily Bodnar initiated coverage on DICE Therapeutics Inc (NASDAQ:DICE) with a Buy rating and a price target of $40 (150%…
HC Wainwright Initiates Coverage On This Nanocrystals Stock
H.C. Wainwright initiated coverage on Clene Inc (NASDAQ:CLNN) with a Buy rating and a $16 price target. Clene is focused on the…
Nestle Bets €40M On Enterome’s Preclinical Food Allergy, IBD Hopeful
France-based Enterome signed a strategic R&D collaboration and license agreement with Nestlé SA’s (OTC:NSRGF) Health Science, targeting food allergies and inflammatory bowel disease…
With Sustained Double-Digit Growth Profile, RBC Starts Coverage On This MedTech Stock
RBC Capital Markets initiated coverage on Penumbra Inc (NYSE:PEN) with an Outperform rating and a price target of $195 (59% implied upside).…